UPPSALA, SWEDEN – LIDDS AB (publ)’s (“LIDDS” or the “Company”) Extraordinary General Meeting was held 11 March 2022 in the Company’s premises in Uppsala. The Extraordinary General Meeting resolved as ...
UPPSALA, SWEDEN – LIDDS AB (publ) announced today the agenda for the Capital Markets Day to be held on March 9, 2022, for investors, analysts and media. Agenda Capital Markets ...
UPPSALA, SWEDEN – LIDDS announced 22 February 2022 that the company had entered into a convertible note agreement with Nice & Green, a Swiss specialty investor, and the company hereby ...
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the company has entered into a convertible note agreement with Nice & Green (“N&G”), a Swiss specialty investor with significant experience ...
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the next step in the development of NanoZolid®-formulated docetaxel (nanodotax) will be to conduct a short clinical study to understand the ...
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will participate at Redeye Fight Cancer Seminar on January 20, 2022. Nina Herne, CEO of LIDDS, will present at ...
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both ...
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in China. The ...
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Johan Harmenberg has been appointed Chief Medical Officer (CMO) of LIDDS AB. Johan Harmenberg has extensive experience from the pharmaceutical sector ...
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that no further patients will be enrolled in its dose escalating Phase I study (NZ-DTX-001) with the primary objective to study safety ...
Copyright © 2015 - 2021 Lifecarenews.in
